GTBP

$5.27+2.73%visit website

GT Biopharma, Inc.

Market Cap

$238M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.76

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

66.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	634	1,376	413	1,055	3,478
Selling, general & administrative	2,748	4,219	2,435	3,457	12,859
Total operating expenses			1,987
Operating income	(3,382)	(5,595)	(2,848)	(4,512)	(16,337)
Interest expense			63.0	64.0
Net income	8,299	(5,708)	(2,833)	(4,518)	(4,760)
EPS (basic) ($)	1.04		(0.11)	(0.12)	—
EPS (diluted) ($)	1.04		(0.11)	(0.12)	—
Weighted avg. shares (basic)	3,941		30,283	38,821
Weighted avg. shares (diluted)	3,941		30,283	38,821

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

11 filings in 12 months · 3 with priority itemsFull history →

Filed	Items	Filing
Sep 25, 2026 accepted 8:10 PM ET	8.01Other events	Document SEC ↗
Sep 21, 2026 accepted 8:10 PM ET	1.01Material agreement3.02Unregistered equity sale3.03Holder rights modified5.03Bylaws / fiscal year	Document SEC ↗
Sep 15, 2026 accepted 12:57 PM ET	1.01Material agreement3.02Unregistered equity sale3.03Holder rights modified5.03Bylaws / fiscal year	Document SEC ↗
Sep 3, 2026 accepted 3:45 PM ET	3.03Holder rights modified5.03Bylaws / fiscal year8.01Other events	Document SEC ↗
Aug 14, 2026 accepted 8:30 PM ET	5.07Shareholder vote	Document SEC ↗
Jun 12, 2026 accepted 8:30 PM ET	5.03Bylaws / fiscal year	Document SEC ↗
May 22, 2026 accepted 12:00 PM ET	3.01Delisting notice	Document SEC ↗
Apr 7, 2026 accepted 11:05 AM ET	1.01Material agreement	Document SEC ↗
Mar 2, 2026 accepted 12:05 PM ET	4.02Non-reliance (restatement)	Document SEC ↗
Nov 26, 2025 accepted 9:30 PM ET	3.01Delisting notice	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

52%

W/W -0.3pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

No Form 4 transactions on record.

Recent News

Gt Biopharma Stock Price Forecast. Should You Buy GTBP?

StockInvest.us · 2026-10-30

GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

Yahoo · 2026-10-26

A study on making pancreatic cancer more vulnerable to immune treatment gets an oral slot

Stock Titan · 2026-10-26

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 2026-10-21

GT Biopharma, Inc. SEC Filing (Oct 21, 2026) | GTBP EFFECT

Stock Titan · 2026-10-21

GT Biopharma Files Prospectus Related To The Offer Up To 13,502,835 Shares Of Common Stock By Selling Stockholders

Benzinga · 2026-10-09

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

Yahoo Finance · 2026-09-16

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

Yahoo Finance · 2026-09-15

GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

Yahoo Finance · 2026-09-11

GT Biopharma Reports Second Quarter 2026 Financial Results

Yahoo Finance · 2026-08-14

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

Yahoo Finance · 2026-06-01

GT Biopharma Reports First Quarter 2026 Financial Results

Yahoo Finance · 2026-05-15

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

Yahoo Finance · 2026-05-14

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

Yahoo Finance · 2026-03-16

Should I buy GT Biopharma (GTBP)

Zacks Investment Research · 2026-03-12

Informational purposes only, not investment advice.

Corporate Events (8-K)

11 filings in 12 months · 3 with priority itemsFull history →

Filed	Items	Filing
Sep 25, 2026 accepted 8:10 PM ET	8.01Other events	Document SEC ↗
Sep 21, 2026 accepted 8:10 PM ET	1.01Material agreement3.02Unregistered equity sale3.03Holder rights modified5.03Bylaws / fiscal year	Document SEC ↗
Sep 15, 2026 accepted 12:57 PM ET	1.01Material agreement3.02Unregistered equity sale3.03Holder rights modified5.03Bylaws / fiscal year	Document SEC ↗
Sep 3, 2026 accepted 3:45 PM ET	3.03Holder rights modified5.03Bylaws / fiscal year8.01Other events	Document SEC ↗
Aug 14, 2026 accepted 8:30 PM ET	5.07Shareholder vote	Document SEC ↗
Jun 12, 2026 accepted 8:30 PM ET	5.03Bylaws / fiscal year	Document SEC ↗
May 22, 2026 accepted 12:00 PM ET	3.01Delisting notice	Document SEC ↗
Apr 7, 2026 accepted 11:05 AM ET	1.01Material agreement	Document SEC ↗
Mar 2, 2026 accepted 12:05 PM ET	4.02Non-reliance (restatement)	Document SEC ↗
Nov 26, 2025 accepted 9:30 PM ET	3.01Delisting notice	Document SEC ↗

GTBP

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

GT Biopharma, Inc. (GTBP)

Factor Profile

Corporate Events (8-K)